CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024
Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value …
Post
-
-
UK and US governments pursue contrasting vaccine strategies
While the outlook for vaccines in the US looks bleak under the current administration, the UK Government is pressing ahead …
-
Actio gains $66m to advance small molecule therapeutics pipeline
US-based Actio Biosciences has closed a Series B financing round, raising $66m to advance the genetics-driven small molecule therapeutics pipeline …
-
BioOrbit eyes 2026 for pre-clinical trials of space manufactured protein crystals
BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory …
-
Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs
In a final blow to Eli Lilly’s Kisunla (donanemab) and Eisai’s Leqembi (lecanemab) UK reimbursement prospects, the National Institute for …
-
Draig secures $140m for neuropsychiatric disorder therapies
Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to advance its portfolio of next-generation therapies …
-
Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) …
-
NHS England chair suggests England can learn from European health schemes
With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics. At …
-
Bavarian Nordic nets $160m from priority review voucher sale
Denmark-based Bavarian Nordic has sold a priority review voucher (PRV) for $160m, a day after the US Food and Drug …
-
Tisento’s MELAS treatment receives fast track status from FDA
Tisento Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its investigational oral medicine, …
-
FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use
US Food and Drug Administration (FDA) Commissioner Dr. Marty Makary addressed concerns about the recent cuts impacting the agency’s ability …
-
Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade
India and the US are on the verge of a trade agreement that will transform commerce between the two largest …
-
Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes
Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients …
-
Orion and Glykos extend ADC collaboration
Orion Corporation has broadened its partnership with Glykos, focusing on the development of antibody-drug conjugates (ADCs). Under the research partnership and …
-
FDA creates new priority review voucher scheme to boost US interests
The US Food and Drug Administration (FDA) has created a new priority review voucher (PRV) framework to expedite the drug …
